19 Comments
 

Moelis and PWP are not that distinguishable in terms of outcomes from Rx shops "above" them in WSO's estimation. The number of Rx analysts is so small that your personal profile i.e. school, GPA, GMAT/SAT become more salient to PE recruiting than prestige hair splitting. 

GHL/Gugg/JEFF Rx are somewhat less easy for PE recruiting but the credit world is sufficiently large and Rx analyst program world small that people get looks from pretty much all Rx programs. 

To OP's question, I have no clue about PFG on-cycle performance so they should just ask an analyst in the group they got an offer from. Comparing the two for re-recruiting for FT is also a black box to me. Having the EB name is good (but not because "it's an EB") and what you actually learn in your internship experience doesn't (or shouldn't, again I don't really have actual first-hand insight here) make you less valuable than your counterpart with an M&A internship.

I will say that Rx SA->FT tends to churn some because SAs from EVR/PJT/HL etc. tend to gun for PE analyst programs and that helps create opportunities for your Gugg Rx intern with their return offer in hand to get a top target group for on-cycle.

 

I think you also want to consider what do you want to do? Those shops are phenominal, just not cranking out 10bn dollar RX plans every Tuesday.

Reneging isn’t too bad, I’ve seen folk do it. Though that connection is definitely gone

 

I have heard some crazy horror stories about the consequences of reneging. Not sure how common these consequences are, but the names that you listed where you would reneg from are strong. I have a friend who interned in an EB doing private funds and he was able to land a PE spot for FT, so PE is definitely an attainable goal from your position.

 

Sorry would be too easy to identify who he is through linkedin, don't want to dox my friend on wso

 

Laborum ullam cupiditate asperiores molestiae et. Excepturi quaerat nihil explicabo nulla similique fugit. Et nesciunt tempora animi.

Asperiores eligendi temporibus quaerat dolores perferendis voluptatem. Et maiores nostrum eum. Distinctio dolores occaecati molestiae asperiores officiis omnis vitae at. Vero molestiae eaque sunt nam. Numquam cum voluptas occaecati. Sed minus cupiditate soluta repudiandae et ratione. Neque cupiditate temporibus non et est.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 04 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (17) $409
  • Associates (58) $261
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (77) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”